Table 4.

Association between characteristics of children and quality of care measured by lung function tests during follow-up in the months 7–12 after start of medication (n = 36,781)

Follow up 7–12 months after start of medical treatment
			P (No.)	PD (95% CI)	PR (95% CI)	Adj. PR (95% CI)	P-values
Gender	Girl		0.23 (3,317)	ref	1	1
	Boys		0.25 (5,599)	0.02 (-0.0–0.03)	1.09 (1.05–1.13)	1.05 (1.01–1.09)	0.008
Age	6–8		0.24 (4,380)	ref	1	1
	9–11		0.25 (3,520)	0.01 (0.0–0.05)	1.02 (0.98–1.06)	1.07 (1.03–1.11)	0.001
	12–14		0.21 (1,016)	-0.03 (-0.04- -0.02)	0.88 (0.83–0.94)	1.01 (0.95–1.07)	0.767
SES	Single		0.23 (1,515)	ref	1	1
	Cohabiting		0.25 (7,389)	0.02 (0.01–0.03)	1.08 (1.03–1.13)	1.06 (1.01–1.11)	0.020
	Education	1	0.24 (5,213)	ref	1	1
		2	0.25 (2,542)	0.01 (0.0–0.02)	1.05 (1.01–1.1)	1.01 (0.97–1.06)	0.627
		3	0.25 (1,149)	0.01 (0.0–0.03)	1.06 (1.0–1.12)	1.05 (0.99–1.11)	0.102
	Income	1	0.24 (1,378)	ref	1	1
		2	0.24 (3,319)	0.00 (-0.02–0.01)	0.99 (0.94–1.05)	0.97 (0.91–1.02)	0.189
		3	0.25 (2,942)	0.00 (-0.01–0.02)	1.01 (0.95–1.06)	0.97 (0.92–1.03)	0.288
		4	0.24 (1,265)	-0.01 (-0.03–0.01)	0.96 (0.90–1.03)	0.92 (0.86–0.99)	0.018
Severity of disease	Mild		0.14 (2,577)	ref	1	1
	Moderate		0.31 (4,090)	0.17 (0.16–0.17)	2.16 (2.06–2.25)	2.15 (2.06–2.24)	< 0.001
	Severe		0.40 (2,249)	0.26 (0.25–0.27)	2.81 (2.68–2.95)	2.79 (2.66–2.93)	< 0.001